These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 29470774)

  • 1. Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations.
    Persson U; Norlin JM
    Appl Health Econ Health Policy; 2018 Apr; 16(2):157-165. PubMed ID: 29470774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pricing Treatments Cost-Effectively when They Have Multiple Indications: Not Just a Simple Threshold Analysis.
    Goldhaber-Fiebert JD; Cipriano LE
    Med Decis Making; 2023; 43(7-8):914-929. PubMed ID: 37698120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indication-specific pricing of pharmaceuticals in the US healthcare system.
    Pearson SD; Dreitlein WB; Henshall C; Towse A
    J Comp Eff Res; 2017 Jul; 6(5):397-404. PubMed ID: 28699779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value-based pricing: Toward achieving a balance between individual and population gains in health benefits.
    Parmar A; Jiao T; Saluja R; Chan KKW
    Cancer Med; 2020 Jan; 9(1):94-103. PubMed ID: 31711274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Indication-Based Pricing in Future Pricing and Reimbursement Policies: A Systematic Review.
    Preckler V; Espín J
    Value Health; 2022 Apr; 25(4):666-675. PubMed ID: 35227598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy.
    Rossini EE; Galeone C; Lucchetti C; Jommi C
    Pharmacoecon Open; 2024 Mar; 8(2):251-261. PubMed ID: 38228997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value-Based Pricing and Budget Impact Analysis for Multi-Indication Drugs: A Case Study of Immunotherapies.
    Ha SY; Kang DW; Jung HI; Lee EK; Park MH
    Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France.
    Drummond M; de Pouvourville G; Jones E; Haig J; Saba G; Cawston H
    Pharmacoeconomics; 2014 May; 32(5):509-20. PubMed ID: 24599784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands.
    Heine RJSD; Mathijssen RHJ; Verbeek FAJ; Van Gils C; Uyl-de Groot CA
    Value Health; 2024 Oct; 27(10):1367-1372. PubMed ID: 38909683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden.
    Davidova J; Praznovcova L; Lundborg CS
    Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland.
    Michaeli DT; Mills M; Kanavos P
    Appl Health Econ Health Policy; 2022 Sep; 20(5):757-768. PubMed ID: 35821360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerating patient access to oncology medicines with multiple indications in Europe.
    Lawlor R; Wilsdon T; Darquennes E; Hemelsoet D; Huismans J; Normand R; Roediger A
    J Mark Access Health Policy; 2021; 9(1):1964791. PubMed ID: 34436506
    [No Abstract]   [Full Text] [Related]  

  • 14. A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden.
    Persson U; Willis M; Odegaard K
    Eur J Health Econ; 2010 Apr; 11(2):195-203. PubMed ID: 19639352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Launch Price and Clinical Value With Reimbursement Decisions for Anticancer Drugs in China.
    Zhou J; Lu H; Pan J
    Int J Health Policy Manag; 2024; 13():8150. PubMed ID: 38618837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.
    Andersson K; Petzold MG; Sonesson C; Lönnroth K; Carlsten A
    Health Policy; 2006 Dec; 79(2-3):231-43. PubMed ID: 16473436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of pricing strategy on the costs of oral anti-cancer drugs.
    Truong J; Chan KKW; Mai H; Chambers A; Sabharwal M; Trudeau ME; Cheung MC
    Cancer Med; 2019 Jul; 8(8):3770-3781. PubMed ID: 31132223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reimbursement and value-based pricing: stratified cost-effectiveness analysis may not be the last word.
    Hawkins N; Scott DA
    Health Econ; 2011 Jun; 20(6):688-98. PubMed ID: 20568075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Price negotiation and pricing of anticancer drugs in China: An observational study.
    Zhou J; Lan T; Lu H; Pan J
    PLoS Med; 2024 Jan; 21(1):e1004332. PubMed ID: 38166148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.